Table 2. XRCC3 Thr241Met polymorphism and response to platinum-based chemotherapy.
| Homozygote Comparison | Heterozygote Comparison | Recessive Model | Dominant Model | |||||||||
| Study | OR(95% CI) | P | Study | OR(95% CI) | P | Study | OR(95% CI) | P | Study | OR(95% CI) | P | |
| Overall | 3 | 1.983 (1.092–3.599)* | 0.868 | 5 | 1.744 (1.169–2.601)* | 0.527 | 3 | 1.390 (0.839–2.303) | 0.343 | 7 | 1.509 (1.099–2.072)* | 0.618 |
| Ethnicity | ||||||||||||
| Asian | NA | NA | 2 | 1.953 (0.745–5.120) | 0.875 | NA | NA | 4 | 1.197 (0.728–1.969) | 0.803 | ||
| Caucasian | 2 | 2.148 (1.073–4.298)* | 0.78 | 2 | 1.349 (0.807–2.254) | 0.638 | 2 | 1.751 (0.967–3.172) | 0.695 | 2 | 1.509 (0.928–2.455) | 0.625 |
| Mixed | 1 | 1.569 (0.483–5.098)* | NA | 1 | 3.243 (1.349–7.795)* | NA | 1 | 0.755 (0.275–2.075) | NA | 1 | 1.509 (1.099–2.072)* | NA |
*
significant difference; Homozygote Comparison: MetMet vs. ThrThr; Heterozygote Comparison: ThrMet vs. ThrThr; Recessive Model: MetMet vs. ThrMet/ThrThr; Dominant Model: ThrMet/MetMet vs. ThrThr; OR: odds ratio; CI: confidence intervals; P: p value of heterogeneity; NA: not available.